Tag: results

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

VERO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of June 2026. The dividend of $0.10 per share will be paid July 30, 2026 to holders of record of the Company’s common stock on June 30, 2026, with an ex-dividend date of June 30, 2026. The Company plans on announcing its next common stock dividend on July 8, 2026.

Paul Miller Rejoins Grocery Outlet as Chief Purchasing and Merchandising Officer
Ian Ferry Promoted to Chief Financial Officer
Company Affirms Second Quarter and Fiscal 2026 Outlook

Net sales increased 22.5% year-over-year to $107.1 million

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Wise Group plc (NASDAQ: WSE) resulting from allegations that Wise Group plc may have issued materially misleading business information to the investing public.

Jiangsu, China, June 09, 2026 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (Nasdaq: MTEN) (the “Company”) today announced that it has entered into a securities purchase agreement with certain institutional investors for the sale of up to 1,131,004 Class A ordinary shares, par value $0.00005 per share (“Class A Ordinary Shares”), at a purchase price of $2.00 per share, and pre-funded warrants to purchase Class A Ordinary Shares at an original exercise price of $2.00, with $1.99995 of the original exercise price pre-funded at the closing, and a remaining exercise price of $0.00005 per Class A Ordinary Share.